Eczema (chronic) - alitretinoin: review decision - October 2012 information
History
A list of downloadable documents created during development.
Background information
Eczema (chronic) - alitretinoin: final appraisal determination
-
Eczema (chronic) - alitretinoin: final appraisal determination information
-
Eczema (chronic) - alitretinoin: final appraisal determination (PDF 130 KB)
-
-
Consultee and commentator comments on the ACD
-
-
Basilea Medical comments on the evaluation report (PDF 22 KB)
-
-
Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham (PDF 16 KB)
-
-
NHS Centre for Reviews & Dissemination and Centre for Health Economics - York (PDF 10 KB)
-
-
-
-
Eczema (chronic) - alitretinoin: appraisal consultation
-
Eczema (chronic) - alitretinoin: appraisal consultation
-
Eczema (chronic) - alitretinoin: appraisal consultation document information
-
Eczema (chronic) - alitretinoin: evaluation report
-
Eczema (chronic) - alitretinoin: pre-meeting briefing (PDF 104 KB)
-
Eczema (chronic) - alitretinoin: Evidence Review Group report (PDF 525 KB)
-
Eczema (chronic) - alitretinoin: non-manufacturer submissions
-
Eczema (chronic) - alitretinoin: Basilea Medical submission (PDF 1.52 MB)
-
Eczema (chronic) - alitretinoin: Royal College of Physicians (PDF 7.9 KB)
-
Eczema (chronic) - alitretinoin: British Contact Dermatitis Society (PDF 42 KB)
-
Eczema (chronic) - alitretinoin: manufacturer submission
-
Eczema (chronic) - alitretinoin: NICE clarification letter (PDF 1.37 MB)
-
Eczema (chronic) - alitretinoin: manufacturer response to clarification letter (PDF 1.37 MB)
-
Eczema (chronic) - alitretinoin: expert written personal statements
-
-
-